182 related articles for article (PubMed ID: 11391594)
1. Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.
Prescott JL; Montie J; Pugh TW; McHugh T; Veltri RW
Cancer; 2001 Jun; 91(11):2127-35. PubMed ID: 11391594
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
3. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
4. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of p53 mutations in bladder washings and histologic specimens.
Vet JA; Hessels D; Marras SA; van de Kaa CA; van der Poel HG; Michalides RJ; Debruyne FM; Schalken JA
Am J Clin Pathol; 1998 Nov; 110(5):647-52. PubMed ID: 9802351
[TBL] [Abstract][Full Text] [Related]
7. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.
Moonen PM; van Balken-Ory B; Kiemeney LA; Schalken JA; Witjes JA
J Urol; 2007 Jan; 177(1):80-3. PubMed ID: 17162008
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma.
Badalament RA; Hermansen DK; Kimmel M; Gay H; Herr HW; Fair WR; Whitmore WF; Melamed MR
Cancer; 1987 Oct; 60(7):1423-7. PubMed ID: 3304614
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
12. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
13. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
16. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
17. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of P53 oncoprotein in urinary wash cytology: experience in patients with superficial bladder carcinoma].
Moreno Sierra J; Luengo Alpuente S; López García-Asenjo J; Redondo González E; Blanco Jiménez E; Fernández Pérez C; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1999 Nov; 52(9):943-54. PubMed ID: 10633962
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method.
Masuda A; Kikuchi YY; Kawamura N
Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510
[TBL] [Abstract][Full Text] [Related]
20. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
